First Manhattan’s ANI Pharmaceuticals ANIP Stock Holding History

First Manhattan’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-269,876	Closed	-$11M	–	1374
2020 Q1	$11M	Buy	269,876 +16,403	+6%	+$872K	0.07%	136
2019 Q4	$15.6M	Hold	253,473	–	–	0.08%	124
2019 Q3	$18.5M	Sell	253,473 -41,379	-14%	-$3.1M	0.1%	115
2019 Q2	$24.2M	Buy	294,852 +54,686	+23%	+$3.89M	0.13%	99
2019 Q1	$16.9M	Buy	240,166 +5,171	+2%	+$304K	0.1%	116
2018 Q4	$10.6M	Buy	234,995 +19,300	+9%	+$1.01M	0.07%	163
2018 Q3	$12.2M	Buy	215,695 +70,000	+48%	+$4.28M	0.07%	166
2018 Q2	$9.73M	Hold	145,695	–	–	0.06%	186
2018 Q1	$8.48M	Hold	145,695	–	–	0.05%	201
2017 Q4	$9.39M	Sell	145,695 -227,900	-61%	-$14.2M	0.05%	194
2017 Q3	$19.6M	Sell	373,595 -2,800	-0.7%	-$134K	0.11%	131
2017 Q2	$17.6M	Buy	376,395 +98,300	+35%	+$4.74M	0.1%	137
2017 Q1	$13.8M	Buy	+278,095	New	+$15.6M	0.08%	148
2016 Q1	–	Sell	-154,336	Closed	-$6.96M	–	1385
2015 Q4	$6.96M	Buy	154,336 +153,736	+25,623%	+$6.62M	0.04%	203
2015 Q3	$23K	Buy	+600	New	+$34.1K	﹤0.01%	1061

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan's ANIP Position: Q2 2020 in Review

First Manhattan sold out of ANI Pharmaceuticals (ANIP) in Q2 2020, closing a stake of 269,876 shares — an estimated $11M sold.

First Manhattan first reported a position in ANIP in Q3 2015 and held it in 15 quarters. The position peaked at $24.2M in Q2 2019. 134 funds tracked by Wall St. Rank hold ANIP as of Q2 2020.

First Manhattan reported no remaining ANI Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
First Manhattan sold 269,876 ANI Pharmaceuticals shares in Q2 2020, an estimated $11M.
First Manhattan first reported a position in ANI Pharmaceuticals in Q3 2015 and held it in 15 quarters.
First Manhattan's ANI Pharmaceuticals position peaked at $24.2M in Q2 2019.
134 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2020.

Based on First Manhattan's 13F filing for Q2 2020, filed 14 Aug 2020.